
Maurizio D'Incalci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1813206/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging. Talanta, 2022, 237, 122918.	5.5	9
2	Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment. Frontiers in Oncology, 2022, 12, 851790.	2.8	10
3	Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. International Journal of Molecular Sciences, 2022, 23, 5786.	4.1	9
4	Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis. European Journal of Cancer, 2022, 171, 85-95.	2.8	8
5	Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell Death and Disease, 2022, 13, .	6.3	2
6	Trabectedin suppresses escape from therapy-induced senescence in tumor cells by interfering with glutamine metabolism. Biochemical Pharmacology, 2022, 202, 115159.	4.4	8
7	Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clinical Lung Cancer, 2021, 22, 361-370.e3.	2.6	8
8	THE SPACE DIMENSION AT THE MICRO LEVEL: MASS SPECTROMETRY IMAGING OF DRUGS IN TISSUES. Mass Spectrometry Reviews, 2021, 40, 201-214.	5.4	16
9	First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. Journal of Thoracic Oncology, 2021, 16, 873-877.	1.1	18
10	Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer—Current Use and Future Opportunities. Cancers, 2021, 13, 2386.	3.7	6
11	Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. Frontiers in Oncology, 2021, 11, 660039.	2.8	28
12	COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). ESMO Open, 2021, 6, 100165.	4.5	4
13	Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers, 2021, 13, 3358.	3.7	9
14	Inhibition of tumorâ€associated macrophages by trabectedin improves the antitumor adaptive immunity in response to antiâ€PDâ€1 therapy. European Journal of Immunology, 2021, 51, 2677-2686.	2.9	18
15	Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma. Genomics, 2021, 113, 3439-3448.	2.9	2
16	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. Journal of Experimental and Clinical Cancer Research, 2021, 40, 286.	8.6	18
17	Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma. Theranostics, 2021, 11, 2987-2999.	10.0	37
18	Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer. Clinical Cancer Research, 2021, 27, 2549-2559.	7.0	34

#	Article	IF	CITATIONS
19	Targeted Therapy. UNIPA Springer Series, 2021, , 181-206.	0.1	0
20	Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Targeted Oncology, 2021, 16, 59-68.	3.6	9
21	Is DNA repair a potential target for effective therapies against malignant mesothelioma?. Cancer Treatment Reviews, 2020, 90, 102101.	7.7	9
22	DNA Damage Response and Immune Defense. International Journal of Molecular Sciences, 2020, 21, 7504.	4.1	66
23	Pharmacokinetics, safety, and activity of trabectedin as firstâ€line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US) Tj ETQ	4 .0. 78 اړ	13 1 14 rgBT /O
24	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. Frontiers in Oncology, 2020, 10, 1287.	2.8	9
25	Optimization of a Luciferase-Expressing Non-Invasive Intrapleural Model of Malignant Mesothelioma in Immunocompetent Mice. Cancers, 2020, 12, 2136.	3.7	3
26	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. Cancers, 2020, 12, 2312.	3.7	5
27	Detection of <i>TP53</i> Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis. JAMA Network Open, 2020, 3, e207566.	5.9	10
28	Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis. BMC Cancer, 2020, 20, 491.	2.6	18
29	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. International Journal of Biological Sciences, 2020, 16, 1363-1375.	6.4	22
30	Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in highâ€grade serous ovarian cancer. International Journal of Cancer, 2020, 147, 565-574.	5.1	15
31	High-dose vitamin C enhances cancer immunotherapy. Science Translational Medicine, 2020, 12, .	12.4	143
32	Abstract LB-268: Detection ofTP53clonal mutations in PAP test collected up to six years prior to high-grade serous epithelial ovarian cancer diagnosis. , 2020, , .		0
33	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. British Journal of Cancer, 2019, 121, 464-473.	6.4	7
34	Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. Journal of Gynecologic Oncology, 2019, 30, e59.	2.2	25
35	Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 2019, 121, 744-750.	6.4	10
36	Multisite analysis of highâ€grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3. International Journal of Cancer, 2019, 145, 2670-2681.	5.1	15

#	Article	IF	CITATIONS
37	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 142, 455-462.	2.9	17
38	Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica, 2019, 104, e222-e223.	3.5	42
39	Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study. Cells, 2019, 8, 1554.	4.1	9
40	Combination of PPARÎ ³ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. Clinical Cancer Research, 2019, 25, 7565-7575.	7.0	15
41	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis, 2019, 40, 303-312.	2.8	28
42	Bone marrow fibroblasts overexpress miRâ€27b and miRâ€214 in step with multiple myeloma progression, dependent on tumour cellâ€derived exosomes. Journal of Pathology, 2019, 247, 241-253.	4.5	74
43	Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. British Journal of Haematology, 2019, 184, 1022-1025.	2.5	5
44	Abstract LB-B13: Lurbinectedin down-regulates ASCL1 transcription factor in Small Cell Lung Cancer (SCLC). , 2019, , .		1
45	Abstract B069: Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells. , 2019, , .		0
46	Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin. Journal of Controlled Release, 2018, 276, 140-149.	9.9	12
47	A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia. Pharmacogenomics Journal, 2018, 18, 56-63.	2.0	8
48	Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. Oncolmmunology, 2018, 7, e1393596.	4.6	58
49	Prompt detection of Lâ€asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. Hematological Oncology, 2018, 36, 498-499.	1.7	Ο
50	Not only tumor but also therapy heterogeneity. Annals of Oncology, 2018, 29, 13-18.	1.2	20
51	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 80-83.	2.3	40
52	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. British Journal of Cancer, 2018, 119, 1456-1463.	6.4	43
53	Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB. Oncotarget, 2018, 9, 19929-19944.	1.8	17
54	Drug-Homogeneity Index in Mass-Spectrometry Imaging. Analytical Chemistry, 2018, 90, 13257-13264.	6.5	6

#	Article	IF	CITATIONS
55	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	10.7	61
56	Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. Analytica Chimica Acta, 2018, 1042, 1-10.	5.4	7
57	Selfâ€Assembling PCLâ€Based Nanoparticles as PTX Solubility Enhancer Excipients. Macromolecular Bioscience, 2018, 18, e1800164.	4.1	9
58	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. British Journal of Cancer, 2018, 119, 565-571.	6.4	15
59	HMCA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene, 2018, 37, 5926-5938.	5.9	24
60	Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer, 2018, 18, 56.	2.6	63
61	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
62	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
63	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	6.4	20
64	High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation. Pharmaceutical Research, 2017, 34, 1180-1186.	3.5	20
65	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European Journal of Cancer, 2017, 76, 84-92.	2.8	26
66	Breast and renal cancer—Derived endothelial colony forming cells share a common gene signature. European Journal of Cancer, 2017, 77, 155-164.	2.8	19
67	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. Cancer Chemotherapy and Pharmacology, 2017, 79, 1267-1271.	2.3	5
68	FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Journal of Experimental and Clinical Cancer Research, 2017, 36, 63.	8.6	53
69	A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. Nature Communications, 2017, 8, 15772.	12.8	102
70	Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm. Handbook of Experimental Pharmacology, 2017, 249, 1-12.	1.8	18
71	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. Cancer Letters, 2017, 388, 320-327.	7.2	73
72	Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiology of Disease, 2017, 99, 12-23.	4.4	149

#	Article	IF	CITATIONS
73	Application of 3D Mass Spectrometry Imaging to TKIs. Clinical Pharmacology and Therapeutics, 2017, 102, 748-751.	4.7	17
74	Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinumâ€free interval: Myth or reality?. Cancer, 2017, 123, 3450-3459.	4.1	48
75	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochemical Pharmacology, 2017, 144, 52-62.	4.4	11
76	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
77	Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. British Journal of Cancer, 2017, 117, 628-638.	6.4	119
78	Mechanism of action of trabectedin in desmoplastic small round cell tumor cells. BMC Cancer, 2017, 17, 107.	2.6	11
79	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. BMC Cancer, 2017, 17, 366.	2.6	16
80	Towards a Model-Based Dose Recommendation for Doxorubicin in Children. Clinical Pharmacokinetics, 2017, 56, 215-223.	3.5	5
81	Promising <i>in vivo</i> efficacy of the BET bromodomain inhibitor OTX015/MKâ€8628 in malignant pleural mesothelioma xenografts. International Journal of Cancer, 2017, 140, 197-207.	5.1	32
82	lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. Clinical Cancer Research, 2017, 23, 2356-2366.	7.0	57
83	A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging. Nanomaterials, 2017, 7, 71.	4.1	13
84	Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial Journal of Clinical Oncology, 2017, 35, 8513-8513.	1.6	2
85	The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget, 2017, 8, 7598-7613.	1.8	79
86	Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. Sarcoma, 2016, 2016, 1-6.	1.3	16
87	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. Scientific Reports, 2016, 6, 39284.	3.3	68
88	Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Scientific Reports, 2016, 6, 22850.	3.3	36
89	Small interfering RNA delivery through positively charged polymer nanoparticles. Nanotechnology, 2016, 27, 125102.	2.6	10
90	Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treatment Reviews, 2016, 50, 175-182.	7.7	38

#	Article	IF	CITATIONS
91	Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus. Cancer Research, 2016, 76, 6657-6668.	0.9	57
92	3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. Scientific Reports, 2016, 6, 37027.	3.3	58
93	Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium―trial. Cancer Chemotherapy and Pharmacology, 2016, 78, 1175-1184.	2.3	25
94	A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment. Annals of Oncology, 2016, 27, 1511-1519.	1.2	20
95	Snail levels control the migration mechanism of mesenchymal tumor cells. Oncology Letters, 2016, 12, 767-771.	1.8	9
96	Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies. Annals of Oncology, 2016, 27, 625-634.	1.2	50
97	PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Molecular Pharmaceutics, 2016, 13, 40-46.	4.6	31
98	Fate of PLA and PCL-Based Polymeric Nanocarriers in Cellular and Animal Models of Triple-Negative Breast Cancer. Biomacromolecules, 2016, 17, 744-755.	5.4	19
99	Tumor-associated macrophages and anti-tumor therapies: complex links. Cellular and Molecular Life Sciences, 2016, 73, 2411-2424.	5.4	99
100	Unique features of trabectedin mechanism of action. Cancer Chemotherapy and Pharmacology, 2016, 77, 663-671.	2.3	132
101	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2016, 77, 477-484.	2.3	13
102	Trabectedin for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2016, 25, 105-115.	4.1	31
103	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. Molecular Cancer Therapeutics, 2016, 15, 125-135.	4.1	56
104	A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study Journal of Clinical Oncology, 2016, 34, 11018-11018.	1.6	4
105	Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies. Oncotarget, 2016, 12, 2404-2417.	1.8	17
106	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget, 2016, 7, 84675-84687.	1.8	42
107	Abstract 1183: PPARgamma agonist promotes adipocytic differentiation and potentiates the activity of trabectedin in myxoid liposarcoma. , 2016, , .		0

Abstract 3764: Trabectedin activity in patient-derived mesothelioma xenografts. , 2016, , .

1

#	Article	IF	CITATIONS
109	Abstract 4821: The WEE1 inhibitor AZD-1775 has synergic activity with trabectedin or lurbinectedin in ovarian cancer cells. , 2016, , .		0
110	Abstract 1284: Lurbinectedin reduces tumor-associated macrophages and the production of inflammatory cytokines, chemokines, and angiogenic factors in preclinical models. , 2016, , .		1
111	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	5.1	50
112	Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin. British Journal of Cancer, 2015, 113, 1687-1693.	6.4	37
113	Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study. Annals of Oncology, 2015, 26, 1363-1371.	1.2	37
114	Targeting the EWS–FLI1 transcription factor in Ewing sarcoma. Cancer Chemotherapy and Pharmacology, 2015, 75, 1317-1320.	2.3	18
115	Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents. Clinical Cancer Research, 2015, 21, 1373-1382.	7.0	39
116	Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. Molecular Cancer Therapeutics, 2015, 14, 2541-2551.	4.1	27
117	HPLC–MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model. Bioanalysis, 2015, 7, 1831-1842.	1.5	7
118	Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors. Biochimie, 2015, 108, 101-107.	2.6	12
119	Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. British Journal of Cancer, 2015, 112, 306-312.	6.4	86
120	Abstract 3777: In silico rendering of cell cycle progression of erlotinib and gemcitabine treatment in pancreatic cancer cells. , 2015, , .		0
121	Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents. , 2015, , .		2
122	Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment. Marine Drugs, 2014, 12, 719-733.	4.6	40
123	Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. BioMed Research International, 2014, 2014, 1-8.	1.9	49
124	microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition. Nature Communications, 2014, 5, 2977.	12.8	226
125	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Annals of Oncology, 2014, 25, 2244-2251.	1.2	153
126	A biodistribution study of PEGylated PCL-based nanoparticles in C57BL/6 mice bearing B16/F10 melanoma. Nanotechnology, 2014, 25, 335706.	2.6	22

#	Article	IF	CITATIONS
127	Investigation of size, surface charge, PEGylation degree and concentration on the cellular uptake of polymer nanoparticles. Colloids and Surfaces B: Biointerfaces, 2014, 123, 639-647.	5.0	50
128	Integrated multiplatform method for <i>in vitro</i> quantitative assessment of cellular uptake for fluorescent polymer nanoparticles. Nanotechnology, 2014, 25, 045102.	2.6	19
129	Immediate Cooling Does Not Prevent the Ex Vivo Hydrolysis of L-Asparagine by Asparaginase. Therapeutic Drug Monitoring, 2014, 36, 549-552.	2.0	19
130	Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles. Nucleic Acids Research, 2014, 42, e96-e96.	14.5	41
131	Quantification of trabectedin in human plasma: Validation of a high-performance liquid chromatography–mass spectrometry method and its application in a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2014, 95, 107-112.	2.8	12
132	Mode of action of trabectedin in myxoid liposarcomas. Oncogene, 2014, 33, 5201-5210.	5.9	111
133	Intratumor Heterogeneity and Its Impact on Drug Distribution and Sensitivity. Clinical Pharmacology and Therapeutics, 2014, 96, 224-238.	4.7	60
134	An integrated approach for the systematic evaluation of polymeric nanoparticles in healthy and diseased organisms. Journal of Nanoparticle Research, 2014, 16, 1.	1.9	12
135	Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth. Clinical Cancer Research, 2014, 20, 1190-1203.	7.0	64
136	Resistance to minor groove binders. Drug Discovery Today: Technologies, 2014, 11, 73-79.	4.0	10
137	Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. British Journal of Cancer, 2014, 111, 646-650.	6.4	180
138	Abstract 5530: OTX015, a novel pan BET-BRD inhibitor is active in non-small-cell lung cancer (NSCLC) cell lines bearing the fusion protein EML4-ALK. Cancer Research, 2014, 74, 5530-5530.	0.9	1
139	Identification of a gene expression driven progression pathway in myxoid liposarcoma. Oncotarget, 2014, 5, 5965-5977.	1.8	16
140	Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study Journal of Clinical Oncology, 2014, 32, e12015-e12015.	1.6	0
141	Abstract 3962: PM01183 shows an improved therapeutic index relative to trabectedin and suppresses EWS/FLI1 activity at clinically achievable concentrations. , 2014, , .		1
142	Abstract 4625: Age dependence of doxorubicin pharmacokinetics in pediatric cancer patients; results of an FP7-funded clinical study. , 2014, , .		0
143	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	7.7	106
144	Synthesis of surfactant free PCL–PEG brushed nanoparticles with tunable degradation kinetics. International Journal of Pharmaceutics, 2013, 453, 551-559.	5.2	45

#	Article	IF	CITATIONS
145	On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 68.	8.6	22
146	Comparison of <i>in vitro</i> and <i>in vivo</i> biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). International Journal of Cancer, 2013, 133, 2024-2033.	5.1	54
147	The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts. Molecular Cancer Therapeutics, 2013, 12, 131-140.	4.1	39
148	Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. European Journal of Cancer, 2013, 49, 520-530.	2.8	141
149	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. European Journal of Cancer, 2013, 49, 290-296.	2.8	74
150	PO71 SAFETY PROFILE AND TOLERABILITY OF TRABECTEDIN AND INDOLE-3-CARBINOL COMBINATION IN REFRACTORY ADVANCED BREAST CANCER. PRELIMINARY RESULTS OF PHASE 1 CLINICAL STUDY. Breast, 2013, 22, S44.	2.2	0
151	Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. Current Opinion in Pharmacology, 2013, 13, 807-812.	3.5	26
152	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013, 23, 249-262.	16.8	721
153	Trabectedin. Oncolmmunology, 2013, 2, e24614.	4.6	49
154	miRNA Landscape in Stage I Epithelial Ovarian Cancer Defines the Histotype Specificities. Clinical Cancer Research, 2013, 19, 4114-4123.	7.0	53
155	The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. European Journal of Cancer, 2013, 49, 1142-1151.	2.8	31
156	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 879-887.	2.3	37
157	Synthesis of Fluorescent PMMAâ€Based Nanoparticles. Macromolecular Materials and Engineering, 2013, 298, 771-778.	3.6	28
158	Trabectedin mechanism of action: what's new?. Future Oncology, 2013, 9, 5-10.	2.4	41
159	Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging. PLoS ONE, 2013, 8, e72532.	2.5	54
160	New activities for the anti-tumor agent trabectedin: taking two birds with one stone. Oncotarget, 2013, 4, 496-497.	1.8	9
161	Abstract B18: miRNA landscape analysis of stage I EOC, identifies miR-199a-5p associated to poor prognosis in grade 3 subgroup. , 2013, , .		0
162	Abstract C161: Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors , 2013, , .		0

#	Article	IF	CITATIONS
163	A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1113-1119.	0.8	149
164	Assessing the anti-tumour properties of Iraqi propolis in vitro and in vivo. Food and Chemical Toxicology, 2012, 50, 1632-1641.	3.6	31
165	The Zinc Finger Gene <i>ZIC2</i> Has Features of an Oncogene and Its Overexpression Correlates Strongly with the Clinical Course of Epithelial Ovarian Cancer. Clinical Cancer Research, 2012, 18, 4313-4324.	7.0	53
166	ls <scp>PDGFR</scp> an important target for Eâ€3810?. Journal of Cellular and Molecular Medicine, 2012, 16, 2838-2839.	3.6	0
167	Targeting DNA repair. Drug Discovery Today: Disease Models, 2012, 9, e39-e41.	1.2	0
168	A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma. PLoS ONE, 2012, 7, e35423.	2.5	19
169	IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. Journal of Ovarian Research, 2012, 5, 3.	3.0	23
170	Characterization of a new trabectedinâ€resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. International Journal of Cancer, 2012, 131, 59-69.	5.1	22
171	Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models. Investigational New Drugs, 2012, 30, 1319-1330.	2.6	7
172	A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemotherapy and Pharmacology, 2012, 69, 1557-1565.	2.3	22
173	Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. Journal of Ovarian Research, 2012, 5, 4.	3.0	19
174	Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS) Journal of Clinical Oncology, 2012, 30, 10047-10047.	1.6	2
175	Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials. Food and Chemical Toxicology, 2011, 49, 2415-2421.	3.6	68
176	Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncology, The, 2011, 12, 273-285.	10.7	173
177	Problems in Dealing with very rare Adverse Effects of New Anticancer Drugs: The Example of Trabectedin. Tumori, 2011, 97, 256-256.	1.1	6
178	Trabectedin in advanced uterine leiomyosarcomas: A retrospective case series analysis from two reference centers. Gynecologic Oncology, 2011, 123, 553-556.	1.4	68
179	Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells. Cancer Chemotherapy and Pharmacology, 2011, 67, 369-379.	2.3	48
180	Development and validation of a highâ€performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis Eâ€3810 in human plasma and its application in a clinical pharmacokinetic study. Journal of Mass Spectrometry, 2011, 46, 1039-1045.	1.6	5

#	Article	IF	CITATIONS
181	E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models. Cancer Research, 2011, 71, 1396-1405.	0.9	131
182	Trabectedin in ovarian cancer: could we expect more?. Annals of Oncology, 2011, 22, 7-8.	1.2	5
183	Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 1709-1719.	4.1	67
184	Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1. , 2011, , .		1
185	Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Tumori, 2011, 97, 256.	1.1	4
186	Abstract 3289: PTX-008, a dual inhibitor of angiogenesis and tumor cell proliferation, potentiates the antineoplastic activity of targeted therapies in human tumor models. , 2011, , .		1
187	Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231. , 2011, , .		Ο
188	Trabectedin therapy for sarcomas. Current Opinion in Oncology, 2010, 22, 342-346.	2.4	40
189	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemotherapy and Pharmacology, 2010, 65, 335-346.	2.3	45
190	Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts. Cancer Chemotherapy and Pharmacology, 2010, 66, 635-641.	2.3	7
191	The Neuroprotective Effect of Erythropoietin in Docetaxel-Induced Peripheral Neuropathy Causes No Reduction of Antitumor Activity in 13762 Adenocarcinoma-Bearing Rats. Neurotoxicity Research, 2010, 18, 151-160.	2.7	22
192	The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo. Biochemical Pharmacology, 2010, 79, 1141-1148.	4.4	116
193	Development and validation of a highâ€performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEPâ€18770 in human plasma and its application in a clinical pharmacokinetic study. Journal of Mass Spectrometry, 2010, 45, 1299-1305.	1.6	8
194	PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene, 2010, 29, 6280-6293.	5.9	103
195	Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors. Clinical Cancer Research, 2010, 16, 4958-4967.	7.0	24
196	A Review of Trabectedin (ET-743): A Unique Mechanism of Action. Molecular Cancer Therapeutics, 2010, 9, 2157-2163.	4.1	372
197	Metabolic Approach to the Enhancement of Antitumor Effect of Chemotherapy: a Key Role of Acetyl- <scp>l</scp> -Carnitine. Clinical Cancer Research, 2010, 16, 3944-3953.	7.0	25
198	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. Cancer Research, 2010, 70, 2235-2244.	0.9	251

#	Article	IF	CITATIONS
199	Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to α1-acid glycoprotein plasma levels. European Journal of Cancer, 2010, 46, 505-516.	2.8	15
200	Reduced Expression of the ROCK Inhibitor Rnd3 Is Associated with Increased Invasiveness and Metastatic Potential in Mesenchymal Tumor Cells. PLoS ONE, 2010, 5, e14154.	2.5	54
201	Genetic Instability Influences Drug Response in Cancer Cells. Current Drug Targets, 2010, 11, 1317-1324.	2.1	21
202	Quantitative Assessment of the Complex Dynamics of G1, S, and G2-M Checkpoint Activities. Cancer Research, 2009, 69, 5234-5240.	0.9	25
203	Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Annals of Oncology, 2009, 20, 1439-1444.	1.2	112
204	Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucleic Acids Research, 2009, 37, 5353-5364.	14.5	152
205	Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Molecular Cancer Therapeutics, 2009, 8, 449-457.	4.1	160
206	Translocation-Related Sarcomas. Seminars in Oncology, 2009, 36, 312-323.	2.2	67
207	Development and validation of a liquid chromatography–tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2009. 877. 3118-3126.	2.3	22
208	Development and validation of a LC–MS/MS method for the determination of the novel oral 1,14 substituted taxane derivatives, IDN 5738 and IDN 5839, in mouse plasma and its application to the pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 4147-4153.	2.3	9
209	Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. Cancer Chemotherapy and Pharmacology, 2009, 63, 563-566.	2.3	14
210	Neuroprotection by erythropoietin against taxane induced peripheral neuropathy. Cytokine, 2009, 48, 53.	3.2	0
211	Adjuvant 5-FU based chemotherapy for colon cancer: Match or miss the mismatch?. European Journal of Cancer, 2009, 45, 316-317.	2.8	2
212	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. European Journal of Cancer, 2009, 45, 1153-1161.	2.8	53
213	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. European Journal of Cancer, 2009, 45, 2116-2122.	2.8	34
214	Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?. European Journal of Cancer, 2009, 45, 2768-2781.	2.8	74
215	The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma. Neoplasia, 2009, 11, 1155-IN7.	5.3	31
216	Abstract B198: The pattern ofin vivobiological activity of Zalypsis® is different from that of trabectedin. , 2009, , .		0

#	Article	IF	CITATIONS
217	Abstract A257: Antitumor activity of Eâ€3810, a new, potent and selective dual inhibitor of VEGF and FGF receptors. , 2009, , .		0
218	Abstract B64: Gene expression profile of a liposarcoma mixoid cell line selectedin vitrofor resistance to Trabectedin. , 2009, , .		0
219	Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced nonâ€smallâ€cell lung cancer by highâ€performance liquid chromatographyâ€tandem mass spectrometry. Journal of Mass Spectrometry, 2008, 43, 216-223.	1.6	25
220	Role of homologous recombination in trabectedin-induced DNA damage. European Journal of Cancer, 2008, 44, 609-618.	2.8	95
221	G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. Clinical Cancer Research, 2008, 14, 7284-7291.	7.0	82
222	Analysis of Gene Expression in Early-Stage Ovarian Cancer. Clinical Cancer Research, 2008, 14, 7850-7860.	7.0	43
223	Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Annals of Oncology, 2007, 18, 561-568.	1.2	22
224	Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy. Current Pharmaceutical Design, 2007, 13, 2744-2750.	1.9	16
225	Metoclopramide treatment in DBA patients: no complete response in a French prospective study. Blood, 2007, 109, 2266-2267.	1.4	26
226	Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth. European Journal of Cancer, 2007, 43, 710-717.	2.8	58
227	Targeting DNA repair as a promising approach in cancer therapy. European Journal of Cancer, 2007, 43, 1791-1801.	2.8	89
228	Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Experimental Neurology, 2007, 204, 317-325.	4.1	228
229	Modulation of response to cancer chemotherapeutic agents by diet constituents – Is the available evidence sufficiently robust for rational advice for patients?. Cancer Treatment Reviews, 2007, 33, 223-229.	7.7	14
230	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology, The, 2007, 8, 595-602.	10.7	416
231	Transfer of a Human Chromosomal Vector from a Hamster Cell Line to a Mouse Embryonic Stem Cell Line. Stem Cells, 2007, 25, 2543-2550.	3.2	15
232	Imatinib concentrations in human milk. Blood, 2007, 109, 1790-1790.	1.4	26
233	Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Proliferation, 2007, 40, 885-904.	5.3	24
234	The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism. Biochemical Pharmacology, 2007, 73, 643-655.	4.4	29

#	Article	IF	CITATIONS
235	Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. Journal of Clinical Investigation, 2007, 117, 3236-3247.	8.2	212
236	Nitrosoureas: molecular pharmacology/ translational research. Tumori, 2007, 93, suppl 17-21.	1.1	0
237	"The Art of Successful Publication―ECCO 13 Workshop Report. European Journal of Cancer, 2006, 42, 434-436.	2.8	8
238	Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. European Journal of Cancer, 2006, 42, 1484-1490.	2.8	85
239	TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. European Journal of Cancer, 2006, 42, 1881-1888.	2.8	62
240	Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemotherapy and Pharmacology, 2006, 57, 1-6.	2.3	57
241	Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemotherapy and Pharmacology, 2006, 58, 319-325.	2.3	17
242	Telomerase Expression in Somatic Cells: Fountain of Youth or Damocles' Sword?. Cell Cycle, 2006, 5, 465-466.	2.6	2
243	Correlation of ErbB2 Gene Status, mRNA and Protein Expression. Oncology Research and Treatment, 2006, 29, 246-247.	1.2	2
244	Pharmacokinetics and Metabolism in Mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a New Oral C-seco-Taxane Derivative with Antiangiogenic Property Effective on Paclitaxel-Resistant Tumors. Drug Metabolism and Disposition, 2006, 34, 2028-2035.	3.3	18
245	A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica, 2006, 91, 24-31.	3.5	66
246	Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anti-Cancer Drugs, 2005, 16, 811-815.	1.4	24
247	The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: A comparative study with SN38 and topotecan. Biochemical Pharmacology, 2005, 70, 1125-1136.	4.4	26
248	N-Acetylcysteine Augments Surface Thiols and Differentially Modulates Cell Adhesion and Invasion in vitro and Metastatic Potential in vivo of B16F1 Melanoma. European Journal of Inflammation, 2005, 3, 17-22.	0.5	0
249	Selective Effects of the Anticancer Drug Yondelis (ET-743) on Cell-Cycle Promoters. Molecular Pharmacology, 2005, 68, 1496-1503.	2.3	37
250	Stepwise Neoplastic Transformation of a Telomerase Immortalized Fibroblast Cell Line. Cancer Research, 2005, 65, 11411-11418.	0.9	40
251	Anti-inflammatory Properties of the Novel Antitumor Agent Yondelis (Trabectedin): Inhibition of Macrophage Differentiation and Cytokine Production. Cancer Research, 2005, 65, 2964-2971.	0.9	263
252	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. Journal of Clinical Oncology, 2005, 23, 1867-1874.	1.6	163

#	Article	IF	CITATIONS
253	Induction of resistance to AplidinÂ [®] in a human ovarian cancer cell line related to MDR expression. Cancer Biology and Therapy, 2005, 4, 1325-1330.	3.4	6
254	Use of cancer chemopreventive phytochemicals as antineoplastic agents. Lancet Oncology, The, 2005, 6, 899-904.	10.7	99
255	Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. European Journal of Cancer, 2005, 41, 323-333.	2.8	21
256	Are we close to the clinical development of novel drugs targeting telomeres and telomerase?. European Journal of Cancer, 2005, 41, 970.	2.8	1
257	Variolin B and its derivate deoxy-variolin B: New marine natural compounds with cyclin-dependent kinase inhibitor activity. European Journal of Cancer, 2005, 41, 2366-2377.	2.8	64
258	Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. Molecular Pharmacology, 2004, 66, 1138-1146.	2.3	134
259	Antiangiogenic activity of aplidine, a new agent of marine origin. British Journal of Cancer, 2004, 90, 2418-2424.	6.4	82
260	Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis,) Tj ETQq0 0 0 rg	BT /Overlc	ock 10 Tf 50 4
261	Determination of Aplidin®, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis, 2004, 34, 619-630.	2.8	18
262	Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. International Journal of Cancer, 2004, 111, 961-967.	5.1	33
263	Cytostatic and Cytotoxic Effects of Topotecan Decoded by a Novel Mathematical Simulation Approach. Cancer Research, 2004, 64, 2825-2832.	0.9	30
264	New Drugs from the Sea. Journal of Chemotherapy, 2004, 16, 86-89.	1.5	20
265	New Molecules and Strategies in the Field of Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 247-262.	7.0	15
266	The Unique Biological Features of the Marine Product Yondelis TM (ET-743, Trabectedin) Are Shared by its Analog ET-637, Which Lacks the C Ring. Oncology Research, 2004, 14, 579-587.	1.5	19
267	Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemotherapy and Pharmacology, 2003, 52, 131-138.	2.3	71
268	High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 113-119.	2.3	23
269	IDN 5390: an oral taxane candidate for protracted treatment schedules. British Journal of Cancer, 2003, 88, 965-972.	6.4	18
270	Effect of Aplidin in acute lymphoblastic leukaemia cells. British Journal of Cancer, 2003, 89, 763-773.	6.4	52

#	Article	IF	CITATIONS
271	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	7.2	142
272	Karyotype instability and anchorage-independent growth in telomerase-immortalized fibroblasts from two centenarian individuals. Biochemical and Biophysical Research Communications, 2003, 308, 914-921.	2.1	49
273	The combination of yondelis and cisplatin is synergistic against human tumor xenografts. European Journal of Cancer, 2003, 39, 1920-1926.	2.8	90
274	Preclinical and clinical results with the natural marine product ET-743. Expert Opinion on Investigational Drugs, 2003, 12, 1843-1853.	4.1	65
275	Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. Molecular Pharmacology, 2003, 63, 632-638.	2.3	27
276	Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood, 2003, 102, 1933-1935.	1.4	16
277	Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clinical Cancer Research, 2003, 9, 625-32.	7.0	159
278	Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Research, 2003, 63, 5902-8.	0.9	50
279	Unique Features of the Mode of Action of ETâ€743. Oncologist, 2002, 7, 210-216.	3.7	44
280	Binding of imatinib by $\hat{l}\pm 1$ -acid glycoprotein. Blood, 2002, 100, 367-369.	1.4	34
281	Differences between in Vivo and in Vitro Sensitivity to Imatinib of Bcr/Abl+ Cells Obtained from Leukemic Patients. Blood Cells, Molecules, and Diseases, 2002, 28, 361-372.	1.4	27
282	Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results―by Albella and colleagues. European Journal of Cancer, 2002, 38, 1297.	2.8	2
283	Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance. Journal of Neuroscience, 2002, 22, 5833-5839.	3.6	233
284	Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. British Journal of Cancer, 2002, 86, 1510-1517.	6.4	54
285	High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 780, 93-98.	2.3	6
286	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clinical Cancer Research, 2002, 8, 3893-903.	7.0	39
287	Cisplatinum and Taxol Induce Different Patterns of p53 Phosphorylation. Neoplasia, 2001, 3, 10-16.	5.3	73
288	Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. European Journal of Cancer, 2001, 37, 97-105.	2.8	218

#	Article	IF	CITATIONS
289	Development of distamycin-related DNA binding anticancer drugs. Expert Opinion on Investigational Drugs, 2001, 10, 1703-1714.	4.1	35
290	High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. Rapid Communications in Mass Spectrometry, 2001, 15, 1807-1816.	1.5	12
291	A novel taxane active against an orthotopically growing human glioma xenograft. Cancer, 2001, 92, 3085-3092.	4.1	18
292	Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. International Journal of Cancer, 2001, 92, 583-588.	5.1	155
293	Cell cycle effects of gemcitabine. International Journal of Cancer, 2001, 93, 401-408.	5.1	73
294	Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase l–II study. Annals of Oncology, 2000, 11, 985-992.	1.2	48
295	Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene, 2000, 19, 2714-2720.	5.9	49
296	Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. British Journal of Cancer, 2000, 82, 524-528.	6.4	8
297	The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemotherapy and Pharmacology, 2000, 45, 495-501.	2.3	27
298	L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Annals of Oncology, 2000, 11, 189-193.	1.2	90
299	Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 6780-6784.	7.1	186
300	p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Research, 2000, 28, 513-519.	14.5	46
301	Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis. Neoplasia, 2000, 2, 202-207.	5.3	22
302	Allelic expression of p73 in human ovarian cancers. Annals of Oncology, 1999, 10, 949-953.	1.2	12
303	The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. Annals of Oncology, 1999, 10, 589-591.	1.2	15
304	Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography–tandem mass spectrometry. Biomedical Applications, 1999, 731, 335-343.	1.7	19
305	High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. Biomedical Applications, 1999, 736, 135-141.	1.7	5
306	Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound. British Journal of Cancer, 1999, 79, 267-277.	6.4	18

#	Article	IF	CITATIONS
307	Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. British Journal of Cancer, 1999, 80, 338-343.	6.4	39
308	Mode of action of thiocoraline, a natural marine compound with anti-tumour activity. British Journal of Cancer, 1999, 80, 971-980.	6.4	86
309	α-Bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity. British Journal of Cancer, 1999, 80, 991-997.	6.4	20
310	Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemotherapy and Pharmacology, 1999, 44, 173-176.	2.3	54
311	Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). Cancer Chemotherapy and Pharmacology, 1999, 44, 403-410.	2.3	16
312	Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Annals of Oncology, 1999, 10, 831-838.	1.2	41
313	Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Annals of Oncology, 1999, 10, 391-395.	1.2	36
314	High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol®) in human plasma. , 1998, 12, 251-255.		56
315	Pharmacokinetics of anticancer agents in patients with impaired liver function. European Journal of Cancer, 1998, 34, 33-46.	2.8	110
316	Molecular characterisation of a panel of human ovarian carcinoma xenografts. European Journal of Cancer, 1998, 34, 1432-1438.	2.8	16
317	Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. European Journal of Cancer, 1998, 34, 1783-1788.	2.8	56
318	The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6-alkylguanine-DNA-alkyltransferase of human tumour xenografts. European Journal of Cancer, 1998, 34, 1749-1755.	2.8	23
319	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research, 1998, 241, 96-101.	2.6	81
320	DNA-topoisomerase I activity and content in epithelial ovarian cancer. Annals of Oncology, 1998, 9, 313-318.	1.2	15
321	Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemotherapy and Pharmacology, 1998, 42, 235-240.	2.3	20
322	IFN-β Partially Counteracts Inhibition of Natural Killer Activity Induced by Some Antitumor Agents. Journal of Interferon and Cytokine Research, 1998, 18, 87-93.	1.2	8
323	hMLH1 and hMSH2 expression and BAX frameshift mutations in ovarian cancer cell lines and tumors. Carcinogenesis, 1998, 19, 691-694.	2.8	14
324	Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Annals of Oncology, 1998, 9, 1315-1322.	1.2	44

#	Article	IF	CITATIONS
325	Some hope from marine natural products. Annals of Oncology, 1998, 9, 937-938.	1.2	4
326	Mechanisms of resistance to alkylating agents. , 1998, , 165-173.		2
327	L-asparagine-depletion: Another opinion. Annals of Oncology, 1997, 8, 204.	1.2	2
328	Differences in docetaxel and paclitaxel activity in resistant tumor cells which express MRP: Need of comparative clinical trials in resistant patients. Annals of Oncology, 1997, 8, 1183-1184.	1.2	0
329	Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome. Annals of Oncology, 1997, 8, 343-350.	1.2	32
330	Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. British Journal of Cancer, 1997, 75, 878-883.	6.4	28
331	DNA minor groove binding ligands: a new class of anticancer agents. Expert Opinion on Investigational Drugs, 1997, 6, 875-884.	4.1	35
332	Expression of Genes of Potential Importance in the Response to Chemotherapy and DNA Repair in Patients with Ovarian Cancer. Gynecologic Oncology, 1997, 65, 130-137.	1.4	53
333	Combination of the new minor groove alkylator tallimustine and melphalan. European Journal of Cancer, 1997, 33, 284-287.	2.8	9
334	Glutathione S-transferase activity and glutathione content in human bladder carcinoma associated with schistosomiasis: comparison with uninvolved surrounding tissues. Cancer Letters, 1997, 121, 19-23.	7.2	7
335	Cell signaling and cancer treatment. Annals of Oncology, 1997, 8, 429-433.	1.2	2
336	Treatment with inhibitors of polyamine biosynthesis, which selectively lower intracellular spermine, does not affect the activity of alkylating agents but antagonizes the cytotoxicity of DNA topoisomerase II inhibitors. British Journal of Cancer, 1997, 75, 1028-1034.	6.4	13
337	DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. British Journal of Cancer, 1997, 76, 474-479.	6.4	60
338	Hematopoietic toxicity and cell cycle perturbations induced by new DNA minor groove–alkylating agents. , 1997, 72, 801-809.		5
339	Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry. , 1997, 11, 1025-1032.		14
340	In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin. European Journal of Cancer, 1996, 32, 2011-2018.	2.8	8
341	Changes in Cyclins and Cyclin-Dependent Kinases Induced by DNA Damaging Agents in a Human Ovarian Cancer Cell Line Expressing Mutated or Wild-Type P53. Experimental Cell Research, 1996, 227, 380-385.	2.6	14
342	L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Annals of Oncology, 1996, 7, 725-730.	1.2	34

#	Article	IF	CITATIONS
343	Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro. British Journal of Cancer, 1996, 73, 525-530.	6.4	9
344	Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Annals of Oncology, 1996, 7, 801-805.	1.2	17
345	3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. British Journal of Cancer, 1996, 73, 861-865.	6.4	17
346	Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. British Journal of Cancer, 1996, 73, 866-871.	6.4	28
347	Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cancer Chemotherapy and Pharmacology, 1996, 38, 541-547.	2.3	28
348	Effects of a novel DNA-damaging agent on the budding yeastSaccharomyces cerevisiae cell cycle. Yeast, 1996, 12, 349-359.	1.7	2
349	Interferon-β can induce progesterone receptors in human endometrial adenocarcinoma. , 1996, 78, 448-453.		3
350	Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. , 1996, 66, 779-783.		104
351	Characterization of a protein recognizing minor groove binders-damaged DNA. Nucleic Acids Research, 1996, 24, 4227-4233.	14.5	5
352	Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Medical and Pediatric Oncology, 1995, 24, 154-159.	1.0	55
353	Isolated bilateral anterior chamber eye relapse in a child with acute lymphoblastic leukemia. Medical and Pediatric Oncology, 1995, 25, 109-112.	1.0	6
354	Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. International Journal of Cancer, 1995, 62, 170-175.	5.1	21
355	High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. Biomedical Applications, 1995, 664, 409-414.	1.7	6
356	Phase I clinical and pharmacokinetic study of oral etoposide phosphate Journal of Clinical Oncology, 1995, 13, 200-209.	1.6	24
357	Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Research, 1995, 23, 1657-1663.	14.5	63
358	DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Research, 1995, 23, 81-87.	14.5	92
359	Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemotherapy and Pharmacology, 1995, 36, 335-340.	2.3	38
360	Clinical Pharmacokinetics of Altretamine. Clinical Pharmacokinetics, 1995, 28, 439-448.	3.5	26

#	Article	IF	CITATIONS
361	Immunoconjugates: The magic bullet revisited or future tumour-targeting therapy?. Annals of Oncology, 1994, 5, 697.	1.2	0
362	Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Research, 1994, 22, 1012-1017.	14.5	52
363	3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis, 1994, 15, 533-537.	2.8	19
364	In vivo anti-tumor activity of synthetic ether lipids is not enhanced by pharmacological modulation of tumor lipid composition. International Journal of Cancer, 1994, 59, 580-581.	5.1	1
365	High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. Biomedical Applications, 1994, 654, 97-102.	1.7	11
366	Determination of l-asparagine in biological samples in the presence of l-asparaginase. Biomedical Applications, 1994, 657, 47-52.	1.7	31
367	Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. British Journal of Cancer, 1994, 69, 205-211.	6.4	16
368	Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. European Journal of Cancer, 1994, 30, 691-696.	2.8	27
369	New approaches in cancer pharmacology: Drug design and development (part 2). European Journal of Cancer, 1994, 30, 1148-1160.	2.8	8
370	Heterogeneous interaction of interferon-Î ² and taxol in human ovarian cancer cells in vitro. European Journal of Cancer, 1994, 30, 892-893.	2.8	1
371	Cell kinetics of human ovarian cancer with in vivo administration of bromodeoxyuridine. Annals of Oncology, 1994, 5, 627-634.	1.2	20
372	DNA-minor-groove alkylators, a new class of anticancer agents. Annals of Oncology, 1994, 5, 877-878.	1.2	8
373	L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives. British Journal of Cancer, 1994, 69, 315-319.	6.4	10
374	Interferon-?? does not change the level of O6-alkylguanine-DNA alkyltransferase in cancer patients?? lymphocytes. Anti-Cancer Drugs, 1994, 5, 601-602.	1.4	1
375	Flow-Cytometric Measurement of Histone H10 in Human Cells. Analytical Biochemistry, 1993, 210, 214-215.	2.4	0
376	Mass spectrometric identification and analysis of some aphidicolin metabolites in cancer patients. Biological Mass Spectrometry, 1993, 22, 351-357.	0.5	0
377	Establishment of l1210 leukemia cells resistant to the distamycin-a derivative (FCE 24517): Characterization and cross-resistance studies. International Journal of Cancer, 1993, 53, 308-314.	5.1	18
378	Intracellular glutathione heterogeneity in L1210 murine leukemia sublines made resistant to dna-interacting anti-neoplastic agents. International Journal of Cancer, 1993, 54, 435-442.	5.1	15

#	Article	IF	CITATIONS
379	Thioanalogues of anti-tumor antibiotics. II. Synthesis and preliminary in vitro cytotoxicity evaluation of tricyclic [1,4]benzothiazepine derivatives. European Journal of Medicinal Chemistry, 1993, 28, 213-220.	5.5	17
380	A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemotherapy and Pharmacology, 1993, 32, 482-486.	2.3	29
381	Cytotoxic activity and mechanism of action of 5-aza-2′-deoxycytidine in human CML cells. Leukemia Research, 1993, 17, 977-982.	0.8	16
382	Cis-diamminedichloroplatinum sensitivity of murine reticulum sarcoma cells in primary culture and after in vitro passages. In Vitro Cellular & Developmental Biology, 1993, 29, 617-619.	1.0	1
383	The effects of a benzoic acid mustard derivative of distamycin a (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents. Biochemical Pharmacology, 1993, 45, 619-626.	4.4	11
384	In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. Journal of Medicinal Chemistry, 1993, 36, 863-870.	6.4	51
385	Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—Dacarbazine and fotemustine—in patients with melanoma. European Journal of Cancer, 1993, 29, 711-719.	2.8	42
386	Cell Growth Inhibitor Constituents From Combretum Kraussii. Natural Product Research, 1993, 1, 273-280.	0.4	8
387	Differential inhibition of the DNA binding of transcription factors NFxB and OTF-1 by nitrogen mustard and quinacrine mustard: transcriptional implications. Carcinogenesis, 1993, 14, 1963-1967.	2.8	13
388	Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Annals of Oncology, 1993, 4, 151-155.	1.2	24
389	Overexpression of p185 is not related to erbB2 amplification in ovarian cancer. Annals of Oncology, 1993, 4, 775-779.	1.2	7
390	Chronic oral etoposide in small-cell lung cancer: Clinical and pharmacokinetic results. Annals of Oncology, 1993, 4, 553-558.	1.2	28
391	Lack of bone marrow toxicity of high-dose cyclophosphamide associated with inefficient drug metabolism. Annals of Oncology, 1993, 4, 895.	1.2	1
392	Low-dose oral etoposide in epithelial cancer of the ovary. Annals of Oncology, 1993, 4, 517-519.	1.2	26
393	O6-Alkylguanine DNA Alkyltransferase Is Induced by Human Recombinant Interferon-αA/D in Mouse Liver. Journal of Interferon Research, 1992, 12, 173-176.	1.2	1
394	Antitumor activity of 1, 4-bis (2'-chloroethyl)-l, 4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis Maleate) in M5076 and its subline resistant to cyclophosphamide M5/CTX. Annals of Oncology, 1992, 3, 233-236.	1.2	2
395	Influence of O6-methylguanine on DNA damage and cytotoxicity of temozoiomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anti-Cancer Drugs, 1992, 3, 401-406.	1.4	26
396	Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin. European Journal of Cancer, 1992, 28, 66-71.	2.8	22

#	Article	IF	CITATIONS
397	Expression of E. coli tag gene encoding 3-methyladenine glycosylase I in NIH-3T3 murine fibroblasts. Biochemical and Biophysical Research Communications, 1992, 185, 41-46.	2.1	5
398	Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma—an effective combination with unexpected toxicity. European Journal of Cancer, 1992, 28, 447-450.	2.8	33
399	Apoptosis Biochemical events and relevance to cancer chemotherapy. FEBS Letters, 1992, 307, 122-127.	2.8	218
400	Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemotherapy and Pharmacology, 1992, 30, 459-464.	2.3	13
401	O 6-Methylguanine-DNA methyltransferase activity and induction of novel immunogenicity in murine tumor cells treated with methylating agents. Cancer Chemotherapy and Pharmacology, 1992, 29, 277-282.	2.3	13
402	Do anticancer agents reach the tumor target in the human brain?. Cancer Chemotherapy and Pharmacology, 1992, 30, 251-260.	2.3	123
403	O 6-Alkylguanine-DNA alkyltransferase content in synchronised human cancer cells. Cancer Chemotherapy and Pharmacology, 1992, 30, 77-80.	2.3	6
404	The unique interaction with immunity of FCE 24517, an antitumor drug with a novel mode of action. International Journal of Immunopharmacology, 1992, 14, 239-251.	1.1	5
405	DNA damage induced by alachlor after in vitro activation by rat hepatocytes. Toxicology, 1992, 72, 207-219.	4.2	36
406	Flowcytometric analysis of multidrug-resistance-associated antigen (P-Glycoprotein) and DNA ploidy in human colon cancer. Journal of Cancer Research and Clinical Oncology, 1992, 118, 575-580.	2.5	11
407	Chinese hamster ovary cells deficient or proficient in O6-alkylguanine-DNA alkyltransferase activity are equally sensitive to X-rays. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 283, 125-129.	1.1	4
408	Studies of the differentiation properties of camptothecin in the human leukaemic cells K562. European Journal of Cancer & Clinical Oncology, 1991, 27, 1406-1411.	0.7	10
409	Nerve cell death induced in vivo by kainic acid and quinolinic acid does not involve apoptosis. NeuroReport, 1991, 2, 651-654.	1.2	40
410	Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with favone acetic acid (FAA). Annals of Oncology, 1991, 2, 145-150.	1.2	6
411	Concentrations of VP16 and VM26 in human brain tumors. Annals of Oncology, 1991, 2, 63-66.	1.2	23
412	Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients. Leukemia Research, 1991, 15, 19-24.	0.8	2
413	Cis dichlorodiammine platinum induced DNA interstrand cross-links in primary cultures of human ovarian cancer. British Journal of Cancer, 1991, 64, 288-292.	6.4	8
414	Notes on the use of in vitro systems to investigate the activity and the mechanism of action of antineoplastic agents. Cytotechnology, 1991, 5, 15-18.	1.6	0

#	Article	IF	CITATIONS
415	Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Research, 1991, 19, 2929-2933.	14.5	125
416	The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961. Journal of Antimicrobial Chemotherapy, 1991, 27, 687-689.	3.0	1
417	Phase I and Clinical Pharmacological Evaluation of Aphidicolin Glycinate. Journal of the National Cancer Institute, 1991, 83, 1160-1164.	6.3	58
418	O6-methylguanine inibits the binding of transcription factors to DNA. Nucleic Acids Research, 1991, 19, 5739-5742.	14.5	25
419	Pharmacokinetics of Intrapleural versus Intravenous Etoposide (VP 16) and Teniposide (VM 26) in Patients with Malignant Pleural Effusion. Oncology, 1990, 47, 55-61.	1.9	7
420	DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate). British Journal of Cancer, 1990, 61, 285-289.	6.4	8
421	Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line. British Journal of Cancer, 1990, 61, 377-381.	6.4	8
422	Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells. Cancer Chemotherapy and Pharmacology, 1990, 26, 340-342.	2.3	11
423	Flavone acetic acid distribution in human malignant tumors. Cancer Chemotherapy and Pharmacology, 1990, 26, 67-70.	2.3	6
424	Flavone acetic acid antitumour activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. Cancer Immunology, Immunotherapy, 1990, 32, 241-244.	4.2	9
425	DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and-resistant human colon carcinoma cells. Cancer Chemotherapy and Pharmacology, 1990, 25, 430-434.	2.3	19
426	Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemotherapy and Pharmacology, 1990, 25, 445-448.	2.3	29
427	Synchronisation of cancer cell lines of human origin using methotrexate. Cytometry, 1990, 11, 595-602.	1.8	18
428	Increase in topoisomerase-II-mediated dna breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate. International Journal of Cancer, 1990, 45, 156-162.	5.1	23
429	Interferon inducers increase O6-alkylguanine-DNA alkyltransferase in the rat liver. Carcinogenesis, 1990, 11, 181-183.	2.8	16
430	In Vitro and In Vivo Effects of Cisplatin on the Generation of Lymphokine-Activated Killer Cells. Journal of the National Cancer Institute, 1990, 82, 139-142.	6.3	22
431	Notes on the Metabolism, Pharmacokinetics and Mode of Action of N-Methyl and N-Ethyl-Triazenes in Relation to Their Pharmacological Activity. , 1990, , 97-107.		0
432	Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Research, 1989, 17, 1051-1059.	14.5	99

#	Article	IF	CITATIONS
433	Induction of Partial Synchronization of Leukemia Cells by Continuous Infusion of Low-Dose Methotrexate Followed by Citrovorum Factor. Journal of the National Cancer Institute, 1989, 81, 1509-1510.	6.3	4
434	Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cellular Immunology, 1989, 120, 250-258.	3.0	35
435	Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin. International Journal of Cancer, 1989, 43, 1091-1097.	5.1	11
436	Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. International Journal of Cancer, 1989, 44, 494-500.	5.1	58
437	A Gas Chromatographic Mass Spectrometric Assay for the Determination of Aphidicolin in Plasma of Cancer Patients. Journal of Pharmaceutical Sciences, 1989, 78, 399-401.	3.3	2
438	Metabolism and pharmacokinetics of p-(3,3-dimethyl-1-triazeno) benzoic acid in M5076 sarcoma-bearing mice. Cancer Chemotherapy and Pharmacology, 1989, 24, 354-358.	2.3	7
439	Flow cytometric analysis of DNA content in human ovarian cancers. British Journal of Cancer, 1989, 60, 45-50.	6.4	62
440	High-performance liquid chromatographic determination of 5-bromodeoxyuridine in human plasma. Biomedical Applications, 1989, 491, 129-138.	1.7	3
441	Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia. European Journal of Cancer & Clinical Oncology, 1989, 25, 1895-1897.	0.7	26
442	Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. Biochemical Pharmacology, 1989, 38, 2069-2075.	4.4	10
443	Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). Biochemical Pharmacology, 1989, 38, 3713-3721.	4.4	21
444	Changes in the synthesis of histone Hl° and Hl in rat FRTL-5 thyroid cells exposed to thyrotropin. Life Sciences, 1989, 45, 2209-2216.	4.3	3
445	Human ovarian tumors in primary culture: Growth, characterization and initial evaluation of the response to cis platinum treatment <i>in vitro</i> . International Journal of Cancer, 1988, 41, 809-818.	5.1	15
446	DNA damage, cytotoxic effect and cell-cycle perturbation of Hoechst 33342 on L1210 cells in vitro. Cytometry, 1988, 9, 1-6.	1.8	46
447	Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemotherapy and Pharmacology, 1988, 22, 47-50.	2.3	14
448	Lack of effect of cisplatin on i. v. L-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemotherapy and Pharmacology, 1988, 22, 87-9.	2.3	7
449	Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347) Tj ETQq1	1 0.78431 6.4	4 rgBT /Ove
450	Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. British Journal of Cancer, 1988, 57, 277-280.	6.4	33

#	Article	IF	CITATIONS
451	DNA interstrand cross-links induced by cis-dichlorodiammine platinum in ovarian cancer cells growing in primary culture. Biochemical Pharmacology, 1988, 37, 1835-1836.	4.4	Ο
452	Intracellular drug concentration and DNA damage in human childhood leukemic cells exposed to doxorubicin. Biochemical Pharmacology, 1988, 37, 1863-1864.	4.4	0
453	Early DNA damage induced in cells exposed to N10-propargyl 5,8-dideazafolic acid (CB 3717) or methotrexate. Biochemical Pharmacology, 1988, 37, 1875-1876.	4.4	3
454	Increase in etoposide-induced topoisomerase II-mediated DNA breaks after cell synchronization induced by low doses of methotrexate. Biochemical Pharmacology, 1988, 37, 1883-1884.	4.4	9
455	Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochemical Pharmacology, 1988, 37, 4423-4431.	4.4	22
456	Doxorubicin induces the acetylation of histone Hl in a human colon cancer cell line (LoVo/DX) selected for resistance to the drug, but not in the sensitive parental line (LoVo). Biochemical and Biophysical Research Communications, 1988, 155, 1221-1229.	2.1	8
457	Effects of cancer disease on the metabolism of anticancer agents. , 1988, 37, 57-65.		6
458	Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717. European Journal of Cancer & Clinical Oncology, 1988, 24, 769-775.	0.7	20
459	Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treatment Reviews, 1988, 15, 279-292.	7.7	121
460	Metabolism of triazine anticancer agents. , 1987, 35, 291-300.		5
461	Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. European Journal of Cancer & Clinical Oncology, 1987, 23, 1529-1535.	0.7	39
462	Histone H1 degrees is synthesized by human lymphocytic leukemia cells but not by normal lymphocytes. Blood, 1987, 70, 1203-1207.	1.4	11
463	Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. Cancer Chemotherapy and Pharmacology, 1987, 20, 239-242.	2.3	21
464	Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors. Cancer Chemotherapy and Pharmacology, 1987, 20, 67-70.	2.3	5
465	Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes. International Journal of Cancer, 1987, 40, 104-107.	5.1	49
466	Comparison of metabolism and activity of an aryldimethyltriazene and an aryldiethyltriazene. Biochemical Pharmacology, 1986, 35, 209-215.	4.4	4
467	Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. European Journal of Cancer & Clinical Oncology, 1986, 22, 173-179.	0.7	18
468	In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemotherapy and Pharmacology, 1986, 16, 125-8.	2.3	7

#	Article	IF	CITATIONS
469	Mitozolomide activity on human cancer cells in vitro. British Journal of Cancer, 1986, 54, 925-932.	6.4	12
470	H1 variant synthesis in proliferating and quiescent human cells. FEBS Journal, 1986, 154, 273-279.	0.2	31
471	Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial. Cancer Chemotherapy and Pharmacology, 1985, 14, 222-8.	2.3	20
472	High-performance liquid chromatographic assay for the determination of p-(3,3-dimethyl-1-triazeno)benzoic acid in mouse plasma. Biomedical Applications, 1985, 345, 323-331.	1.7	3
473	A filter incubation method for the determination of potentially crosslinkable sites in DNA in mammalian cells. Analytical Biochemistry, 1985, 150, 161-165.	2.4	6
474	Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213. Identification of a new metabolite. Chemico-Biological Interactions, 1985, 55, 215-224.	4.0	10
475	Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver. Xenobiotica, 1985, 15, 343-350.	1.1	17
476	Etoposide (VP-16-213) in malignant brain tumors: a phase II study Journal of Clinical Oncology, 1984, 2, 432-437.	1.6	94
477	Comparison of the antitumor activity of DTIC and 1-p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on murine transplantable tumors and their hematological toxicity. Cancer Chemotherapy and Pharmacology, 1984, 13, 139-41.	2.3	8
478	Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients. Cancer Chemotherapy and Pharmacology, 1984, 13, 211-214.	2.3	10
479	Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma. Biochemical Pharmacology, 1984, 33, 2715-2722.	4.4	2
480	Central side effects of pentamethylmelamine: Biochemical and behavioural studies. Biochemical Pharmacology, 1984, 33, 4011-4015.	4.4	1
481	Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Cancer Chemotherapy and Pharmacology, 1983, 10, 208-11.	2.3	16
482	Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum. Cancer Chemotherapy and Pharmacology, 1983, 11, 33-4.	2.3	7
483	Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma. Cancer Chemotherapy and Pharmacology, 1983, 11, 51-5.	2.3	14
484	Metabolism of the anticancer agent 1-(4-acetylphenyl)-3,3-dimethyltriazene. Biomedical Mass Spectrometry, 1983, 10, 485-488.	1.9	10
485	TRANSPLACENTAL PASSAGE OF DOXORUBICIN. Lancet, The, 1983, 321, 75.	13.7	30
486	ICRF 159 Plus Radiation Versus Radiation Therapy Alone in Cervical Carcinoma. Oncology, 1983, 40, 181-185.	1.9	4

#	Article	IF	CITATIONS
487	In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma. European Journal of Cancer & Clinical Oncology, 1982, 18, 377-380.	0.7	26
488	Routes of elimination of hexamethylmelamine and pentamethylmelamine in the rat. Xenobiotica, 1982, 12, 315-321.	1.1	5
489	Studies of the mode of action of antitumour triazenes and triazines—III. Metabolism studies on hexamethylmelamine. Biochemical Pharmacology, 1982, 31, 625-631.	4.4	14
490	Studies of the mode of action of antitumour triazenes and triazines—IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene. Biochemical Pharmacology, 1982, 31, 1887-1892.	4.4	14
491	Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Cancer Chemotherapy and Pharmacology, 1982, 7, 127-31.	2.3	26
492	Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemotherapy and Pharmacology, 1982, 7, 141-5.	2.3	108
493	High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy. Gynecologic Oncology, 1981, 12, 314-318.	1.4	39
494	Influence of ascites on the pharmacokinetics of hexamethylmelamine andN-demethylated metabolites in ovarian cancer patients. European Journal of Cancer & Clinical Oncology, 1981, 17, 1331-1335.	0.7	16
495	High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene β-d-glucopyranoside) (VP 16-213) in human plasma. Biomedical Applications, 1981, 222, 141-145.	1.7	57
496	Dose-dependent pharmacokinetics of PMM in the rat. Cancer Chemotherapy and Pharmacology, 1981, 5, 201-203.	2.3	5
497	Hexamethylmelamine Tissue Concentrations in Pelvic Cancer Patients. Therapeutic Drug Monitoring, 1980, 2, 187-188.	2.0	1
498	Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. Cancer Chemotherapy and Pharmacology, 1980, 4, 129-32.	2.3	25
499	Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites. British Journal of Cancer, 1980, 41, 630-635.	6.4	22
500	Pharmacokinetic Approach to <i>in vitro </i> Testing of Ovarian Cancer Cell Sensitivity. Oncology, 1980, 37, 169-173.	1.9	5
501	N-hydroxymethylpentamethylmelamine, a major metabolite of hexamethylmelamine. Life Sciences, 1980, 26, 147-154.	4.3	46
502	Clinical Relevance of Pharmacokinetics. Clinical Pharmacokinetics, 1980, 5, 105-136.	3.5	13
503	Gas chromatographic determination of hexamethylmelamine in mouse plasma. Analytical Biochemistry, 1979, 99, 441-449.	2.4	18
504	Decreased half life of cyclophosphamide in patients under continual treatment. European Journal of Cancer, 1979, 15, 7-10.	0.9	65

#	Article	IF	CITATIONS
505	Pharmacokinetics of Cyclophosphamide after prolonged low dose treatment in ovarian cancer patients. European Journal of Drug Metabolism and Pharmacokinetics, 1979, 4, 83-85.	1.6	5
506	Laparoscopy and Peritoneal Cytology as Markers in the Follow-Up of Ovarian Epithelial Tumors. Recent Results in Cancer Research, 1979, 68, 146-151.	1.8	1
507	Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen—phosphorus-selective detector. Biomedical Applications, 1978, 145, 315-318.	1.7	19
508	Adriamycin in ovarian cancer patients resistant to cyclophosphamide. European Journal of Cancer, 1978, 14, 1401-1402.	0.9	20